Search results

Skip to results

Type

Status

Last updated

Showing 1 to 6 of 6 results for eptinezumab

  1. Eptinezumab for preventing migraine (TA871)

    Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    1 March 2023
    View recommendations

    Sections for TA871

  2. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA973

  3. Eptinezumab for preventing cluster headache attacks TSID 12087

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  5. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA906

  6. Headaches in over 12s: diagnosis and management (CG150)

    This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.

    Clinical guideline
    Last updated
    3 June 2025
    View recommendations

    Sections for CG150